Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.

  2. Drug

    Rocuronium

    go.drugbank.com/drugs/DB00728
    ApprovedInvestigational

    It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery … The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma.

    Products: Rocuroniumbromid Aguettant 10 mg/ml Injektionslösung in einer Fertigspritze
  3. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. … In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.

  4. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

  5. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063] … increasing the signalling of other neurotransmitters in the brain.

  6. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    in combination with chemotherapy or on its own [L941]. … The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).

  7. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. … It is suspended in 0.9% sodium chloride solution, and heat-sterilized.

  8. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    in the patient populations being studied [A31551]. … It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups.

  9. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51103,L51108] It has also been available in Japan since 2020 under the brand name Ecclock.[L51103] … [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.

  10. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. … [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]